Acotec Scientific Holdings Limited

HKSE 6669.HK

Acotec Scientific Holdings Limited Current Liabilities for the year ending December 31, 2023: USD 16.37 M

Acotec Scientific Holdings Limited Current Liabilities is USD 16.37 M for the year ending December 31, 2023, a 14.51% change year over year. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.
  • Acotec Scientific Holdings Limited Current Liabilities for the year ending December 31, 2022 was USD 14.30 M, a 3.11% change year over year.
  • Acotec Scientific Holdings Limited Current Liabilities for the year ending December 31, 2021 was USD 13.87 M, a -77.60% change year over year.
  • Acotec Scientific Holdings Limited Current Liabilities for the year ending December 31, 2020 was USD 61.91 M, a 628.41% change year over year.
  • Acotec Scientific Holdings Limited Current Liabilities for the year ending December 31, 2019 was USD 8.50 M.
Key data
Date Current Liabilities Total Non-Current Liabilities Shareholders' Equity Long-Term Debt
Market news
Loading...
SV Wall Street
HKSE: 6669.HK

Acotec Scientific Holdings Limited

CEO Ms. Jing Li
IPO Date Aug. 24, 2021
Location China
Headquarters Building No. 1
Employees 615
Sector Health Care
Industries
Description

Acotec Scientific Holdings Limited, a medical device company, researches and develops percutaneous transluminal angioplasty and drug-coated balloon products for the treatment of vascular diseases in Mailand China, Europe, and internationally. It offers AcoArt Orchid & Dhalia to prevent stenosis or occlusion in superficial femoral artery and popliteal artery for the treatment of lower extremity artery disease; under clinical studies in nephrology for arteriovenous fistula stenosis and in neurology for vertebral atherosclerotic stenosis indications/applications; and under clinical studies in andrology for vasculogenic erectile dysfunction indications/applications. The company also provides AcoArt Tulip & Litos, which is under registration process in China and Europe, and under preclinical studies in the United States in vascular surgery for below-the-knee artery disease indications/applications; and in pre-clinical studies in andrology for vasculogenic erectile dysfunction indications/applications. The company was incorporated in 2020 and is headquartered in Beijing, China. Acotec Scientific Holdings Limited is a subsidiary of CA Medtech Investment (Cayman) Limited.

Similar companies

2190.HK

Zylox-Tonbridge Medical Technology Co., Ltd.

USD 1.41

-0.92%

6699.HK

Angelalign Technology Inc.

USD 6.93

1.87%

6608.HK

Bairong Inc.

USD 1.06

0.47%

StockViz Staff

January 31, 2025

Any question? Send us an email